Nottingham
Patients and Methods
The screening procedure costed is shown in strict field protocol such as the one used in the pilot study. It was assumed that half of the patients requiring a second lOP screen with normal fields would maintain a high pressure and be referred to an eye outpatient depart ment, the rest being regarded as normal. Initial screening would take place in general practices undertaken by a nurse supported by a clerk. The nurse would undertake the screening procedure and the clerk would be responsible for sending out invitations and following up non attenders. The screening could be done by a trained technician but for the purposes of this exercise, it was assumed that a nurse (Grade G) would be suitable.
The time taken for each test, including explanation, was measured, as was that involved in identifying patients, sending out invitations and organising screening sessions. These times were used to estimate the total population that could be screened per annum if a full time trained nurse and clerk were employed. A non-attendance rate of 20% was used in the calculations. Half the nurse's time was assumed to be spent on initial screening, the rest on performing fields, second stage lOP screening and organisation. The screen ing programme would be under the overall supervision of a consultant ophthalmologist and the time necessary for this was estimated.
Staff costs were based on the mid point of the relevant salary scale with additions for insur ance and superannuation. The costs of a hos pital outpatient assessment for those requiring one were included as part of the screening programme. The cost of an out patient visit was estimated on the basis of average medical, nursing and clerical staff costs per outpatient visit obtained from Health Service costing returns. H Postage and stationery costs were included, these were mainly for sending out invitations and reminder letters. It was assumed that both nurse and clerk would be based in the eye outpatient department but would travel from practice to practice. Annual costs of the Pulsair non contact tonometer and Henson CFS 2000 field screener were calculated from list prices. Both items of equipment were assumed to have a life span of five years and costs were discounted at 4% per annum.
An additional 30% was added to all esti mated costs for overheads, this figure being chosen as reflecting other Health Service costs, but it is probably an overestimate for a peripatetic service such as this.
Results
Using the Pulsair tonometer, eight measures of intraocular pressure can be taken in an average of two minutes.6 The average total time per screen, including explanations to the patient, was estimated at three minutes. Thus a full time nurse was estimated to be able ' to hold screening sessions for 12,500 patients per annum. On the basis of a 20 per cent non attendance rate, 10,000 would actually be screened. On the basis of the pilot study, 126 true cases of glaucoma would be expected to be identified in such a populat!on. A further 206 patients would also have raIsed pressures at their second screen and be referred to the Eye Outpatient Department but be classified as false positives.
The total cost of an outpatient visit was esti mated at £17.33. This figure included medical staff costs of £6.02, nursing staff costs of £2.95, equipment and drugs costs ofO.50p and £7.86 for general services. We assumed screening for glaucoma to be necessary every five years and the annual costs of screening are shown in Table I . It should be noted that the total annual costs include the cost of hos pital outpatient review of patients with abnormal results. The total Health Service cost per patient screened therefore amounts to £3.35, with a cost of £311.00 per case of treatable glaucoma detected.
In a five year time period the nurse and clerk team would be able to invite 62,500 indi viduals aged 50 years and over for screening. Assuming that 50,000 attended then a total of 1660 patients would have positive screens of whom 630 would require treatment.
Discussion
Ten per cent of patients with glaucoma are registerable as blind on presentation.3 The rationale for screening for glaucoma is that early detection and prompt treatment will prevent or delay the onset of visual loss. This has obvious benefits for the patients con cerned, who will retain a better quality of life.
The prevention of blindness also has benefits to society as a whole. Patients live approxi mately ten years following blind registration for glaucoma,9 and glaucoma accounts for 14 per cent of blind registrations in Notting ham.w As treatment can prevent or delay blindness, major savings would be expected in the provision of special care, including the adaptation of housing, the provision of special aids and in tax deductions. Although measurement of these costs was not Table I Annual cos ts of a general practice based screening programme (10,000 screens per year). attempted in this study, they are thought to be significantly greater than the estimated cost per case detected.
The importance of early detection of glau coma has been acknowledged by the govern ment provision of free eye tests by an optometrist for those with recognised risk fac tors. From April 1 1989 only diabetics and those with a positive family history of glau coma will be entitled to such a test on medical grounds. Whilst these individuals are at greater risk of developing glaucoma, only 42% of cases detected in our pilot study had either of these risk factors.1>
The fee paid to optometrists for screening such individuals is £10.70, considerably more than the estimated £3.55 per screen if popula tion screening were introduced, although only 7% of the population would be screened. If optometrists could achieve similar sensitivity and specificity results to those found in our screening study, the minimum cost per case detected would be £201.00. This does not include a costing for the identification of high risk individuals, which may be difficult and therefore substantial.
Detecting glaucoma in the higher risk groups using optometrists may, therefore, cost as much or even more per case detected, particularly as optometrist specificities esti mated from recent studies vary consider ably.4.11 Even if it proves to be relatively cheaper, consideration needs to be given to the relative costs of detecting all cases rather than those simply occurring in high risk groups.
In our feasibility study 90% of patients requiring treatment were detected simply using measurement of intraocular pressures, with field analysis only if lOP exceeded 22mmHg.
An argument against tonometry as the primary screening tool in chronic simple glau coma (CSG) is the reported low sensitivity of the method. For example, Hollows and Gra ham found that only 50% of indivi"duals with classical CSG detected in a screening study had lOP s >21 mmHg initiallyY However, no mention is made of the maximum lOP in these individuals.
The importance of value for money has been emphasised by a recent editorial on screening. 13 The risk of development or pro gression of field loss increases as presenting lOP rises in CSGI4 and the higher the lOP, the more aggressive the glaucoma. IS Therefore, there will be a greater cost/benefit ratio in identifying subjects with the higher lOPs, particularly as treatment at present concen trates on lowering lOP.
Applying the results of our pilot study," we calculate that the addition of routine field analysis to the protocol, without experienced fundal assessment, increases the cost per case detected to £415, an increase of 33%. This is mainly as a result of increased false positives requiring hospital assessment.
Alternatively, employing a staff grade oph thalmologist or optometrist as part of the screening programme to perform disc assess ment, was estimated to increase the Health Service cost per case detected by approxi mately £150.00, an increase of almost 50%.
We believe the cost per case detected as cal culated in this study (£311) is not so prohibi tively high to rule out community screening for glaucoma. Generous timings for the organisation of the programme were included when estimating the costs in this study. Such a programme should not be implemented, how ever, without considering the consequences to the Hospital Eye Service. The initial diagnos tic visit is included in this costing and there would be a reduction in referrals to ophthal mic clinics for 'query glaucoma', which pres ently run at 14% of all referrals to a general ophthalmologist. II This must be set against the extra workldad involved in managing the occult cases detected by the screening programme.
The development of a screening pro gramme on a trial basis is necessary to deter mine its feasibility across a range of general practices. The present population involved in this study is not atypical but it may be unre alistic to expect the high response achieved from patients in all areas. For example, inner city practices have notoriously low levels of attendance for screening clinics.
In order to determine whether community screening on a nationwide scale would be efficient in preventing visual deficit from glau coma, a carefully audited study is required. It must include sufficient individuals in matched groups to ensure a statistically significant result. We are at present designing such a study.
